Skip to main content

Table 2 CRP levels

From: Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab

  Before cCRT Before Durvalumab 3-month follow-up 6-month follow-up 9-month follow-up 12-month follow-up
Patient values 22 22 22 19 19 18
CRP ≤5 20 (91%) 21 (95%) 19 (86%) 17 (89%) 18 (95%) 18 (100%)
CRP > 5 2 (9%) 1 (5%) 3 (14%) 2 (11%) 1 (5%) 0